SEC Comment Letter for Cellectis S.A. (CLLS) (CIK 0001627281) (CLLS) — Oct 31, 2017
Cellectis S.A. (CLLS) (CIK 0001627281)
Date: Oct. 31, 2017 · CIK: 0001627281 · Accession: 0000000000-17-038517
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-36891
Letter
October 31, 2017 Marie-Bleuenn Terrier General Counsel Cellectis S.A. 8, rue de la Croix Jarry 75013 Paris, France Re:Cellectis S.A. Form 20-F for the Fiscal Year Ended December 31, 2016 Filed March 23, 2017 File No. 001-36891 Dear Ms. Terrier: We have reviewed your October 10, 2017 response to our comment letter and have the following comment. Please respond to the comment within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to the comment, we may have additional comments. Form 20-F for the Fiscal Year Ended December 31, 2016 Current Intellectual Property Portfolio, page 76 1.We refer to your proposed disclosure in response to comment 1, and note that issued patents relating to your gene-editing platform and T-cell and CAR technology platforms have upcoming expiration dates in 2019. In future filings, please also discuss whether you expect the expiration of these patents to have a material effect on your business, including any impact on future operations and the financial position of the company.
FirstName LastNameMarie-Bleuenn Terrier Comapany NameCellectis S.A. June 16, 2017 Page 2 FirstName LastName Marie-Bleuenn Terrier Cellectis S.A. October 31, 2017 Page 2
Please contact Chris Edwards at (202) 551-6761 or Erin Jaskot at (202) 551-3442 with any questions. Division of Corporation Finance Office of Healthcare & Insurance
Show Raw Text
October 31, 2017
Marie-Bleuenn Terrier
General Counsel
Cellectis S.A.
8, rue de la Croix Jarry
75013 Paris, France
Re:Cellectis S.A.
Form 20-F for the Fiscal Year Ended December 31, 2016
Filed March 23, 2017
File No. 001-36891
Dear Ms. Terrier:
We have reviewed your October 10, 2017 response to our comment letter and have the
following comment.
Please respond to the comment within ten business days by providing the requested
information or advise us as soon as possible when you will respond. If you do not believe our
comment applies to your facts and circumstances, please tell us why in your response.
After reviewing your response to the comment, we may have additional comments.
Form 20-F for the Fiscal Year Ended December 31, 2016
Current Intellectual Property Portfolio, page 76
1.We refer to your proposed disclosure in response to comment 1, and note that issued
patents relating to your gene-editing platform and T-cell and CAR technology
platforms have upcoming expiration dates in 2019. In future filings, please also discuss
whether you expect the expiration of these patents to have a material effect on your
business, including any impact on future operations and the financial position of the
company.
FirstName LastNameMarie-Bleuenn Terrier
Comapany NameCellectis S.A.
June 16, 2017 Page 2
FirstName LastName
Marie-Bleuenn Terrier
Cellectis S.A.
October 31, 2017
Page 2
Please contact Chris Edwards at (202) 551-6761 or Erin Jaskot at (202) 551-3442 with
any questions.
Division of Corporation Finance
Office of Healthcare & Insurance